Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Gains from Investment Securities (2019 - 2022)

Historic Gains from Investment Securities for Avidity Biosciences (RNA) over the last 4 years, with Q3 2022 value amounting to $9.1 million.

  • Avidity Biosciences' Gains from Investment Securities changed N/A to $9.1 million in Q3 2022 from the same period last year, while for Dec 2024 it was $12.1 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.7 million for FY2023, which is N/A changed from last year.
  • Per Avidity Biosciences' latest filing, its Gains from Investment Securities stood at $9.1 million for Q3 2022.
  • In the past 5 years, Avidity Biosciences' Gains from Investment Securities ranged from a high of $12.1 million in Q4 2021 and a low of -$4000.0 during Q2 2019
  • In the last 4 years, Avidity Biosciences' Gains from Investment Securities had a median value of $5.8 million in 2021 and averaged $5.2 million.
  • In the last 5 years, Avidity Biosciences' Gains from Investment Securities surged by 7165000.0% in 2020 and then skyrocketed by 4977.45% in 2022.
  • Quarter analysis of 4 years shows Avidity Biosciences' Gains from Investment Securities stood at -$4000.0 in 2019, then skyrocketed by 6600.0% to $260000.0 in 2020, then skyrocketed by 4537.69% to $12.1 million in 2021, then fell by 24.59% to $9.1 million in 2022.
  • Its Gains from Investment Securities was $9.1 million in Q3 2022, compared to $8.6 million in Q2 2022 and $8.3 million in Q1 2022.